X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15612) 15612
Newsletter (109) 109
Book Chapter (64) 64
Magazine Article (22) 22
Newspaper Article (6) 6
Publication (5) 5
Dissertation (4) 4
Report (4) 4
Web Resource (2) 2
Government Document (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13384) 13384
female (10116) 10116
science & technology (9190) 9190
life sciences & biomedicine (9056) 9056
male (7648) 7648
cyclophosphamide - administration & dosage (7366) 7366
middle aged (7362) 7362
adult (6908) 6908
cyclophosphamide - adverse effects (6908) 6908
antineoplastic combined chemotherapy protocols - therapeutic use (5191) 5191
aged (4947) 4947
cyclophosphamide (4687) 4687
antineoplastic combined chemotherapy protocols - adverse effects (4618) 4618
oncology (4429) 4429
cyclophosphamide - therapeutic use (4263) 4263
treatment outcome (2958) 2958
doxorubicin - administration & dosage (2925) 2925
adolescent (2537) 2537
hematology (2534) 2534
chemotherapy (2531) 2531
vincristine - administration & dosage (2344) 2344
breast neoplasms - drug therapy (2177) 2177
antineoplastic combined chemotherapy protocols - administration & dosage (1939) 1939
abridged index medicus (1935) 1935
doxorubicin - adverse effects (1900) 1900
cancer (1888) 1888
animals (1746) 1746
child (1676) 1676
prednisone - administration & dosage (1561) 1561
vincristine - adverse effects (1553) 1553
combined modality therapy (1537) 1537
drug therapy, combination (1499) 1499
retrospective studies (1467) 1467
drug administration schedule (1380) 1380
prognosis (1373) 1373
care and treatment (1348) 1348
follow-up studies (1334) 1334
immunosuppressive agents - therapeutic use (1256) 1256
methotrexate - administration & dosage (1227) 1227
disease-free survival (1226) 1226
transplantation (1188) 1188
etoposide - administration & dosage (1180) 1180
prednisone - adverse effects (1174) 1174
time factors (1171) 1171
rituximab (1154) 1154
antineoplastic agents - adverse effects (1144) 1144
breast cancer (1138) 1138
remission induction (1120) 1120
child, preschool (1109) 1109
fluorouracil - administration & dosage (1072) 1072
medicine & public health (1025) 1025
neoplasm staging (1022) 1022
immunosuppressive agents - adverse effects (1008) 1008
aged, 80 and over (1001) 1001
vincristine - therapeutic use (1001) 1001
survival rate (986) 986
prednisone - therapeutic use (980) 980
survival analysis (980) 980
risk factors (979) 979
doxorubicin - therapeutic use (957) 957
dose-response relationship, drug (952) 952
prospective studies (949) 949
methotrexate - adverse effects (931) 931
immunology (923) 923
young adult (913) 913
cisplatin - administration & dosage (901) 901
mice (842) 842
breast neoplasms - pathology (818) 818
research (816) 816
lymphoma, non-hodgkin - drug therapy (811) 811
health aspects (779) 779
analysis (761) 761
recurrence (745) 745
patients (723) 723
fluorouracil - adverse effects (709) 709
lymphomas (706) 706
antineoplastic agents - therapeutic use (703) 703
clinical trials as topic (688) 688
pharmacology & pharmacy (673) 673
drug therapy (669) 669
etoposide - adverse effects (653) 653
rheumatology (645) 645
anthracyclines (643) 643
lymphoma, large b-cell, diffuse - drug therapy (627) 627
bone marrow transplantation (597) 597
chemotherapy, adjuvant (597) 597
infant (591) 591
antineoplastic agents - administration & dosage (580) 580
epirubicin - administration & dosage (573) 573
methotrexate - therapeutic use (570) 570
immunosuppressive agents - administration & dosage (557) 557
clinical trials (553) 553
general & internal medicine (552) 552
doxorubicin (548) 548
stem cells (547) 547
lung neoplasms - drug therapy (540) 540
medicine, general & internal (523) 523
cisplatin - adverse effects (515) 515
pediatrics (515) 515
transplantation, autologous (514) 514
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14525) 14525
Japanese (397) 397
German (380) 380
French (211) 211
Russian (156) 156
Chinese (153) 153
Spanish (141) 141
Italian (64) 64
Polish (53) 53
Portuguese (35) 35
Hungarian (21) 21
Dutch (17) 17
Czech (14) 14
Norwegian (13) 13
Danish (11) 11
Slovak (7) 7
Bulgarian (5) 5
Swedish (5) 5
Korean (4) 4
Croatian (3) 3
Romanian (3) 3
Serbian (3) 3
Turkish (3) 3
Ukrainian (3) 3
Hebrew (2) 2
Finnish (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 05/2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | Radiotherapy Dosage | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Book Review
The New England journal of medicine, ISSN 1533-4406, 07/2011, Volume 365, Issue 3, pp. 203 - 212
.... BEACOPP therapy was associated with higher initial rates of complete response and freedom from relapse but also with more short-term and long-term toxic effects... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 01/2013, Volume 31, Issue 2, pp. 231 - 239
Purpose To optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during survivorship, information on the impact of chemotherapy... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Gonadotropin-Releasing Hormone - analogs & derivatives | Fertility - physiology | Fertility Preservation | Young Adult | Vinblastine - adverse effects | Follicle Stimulating Hormone - blood | Hodgkin Disease - drug therapy | Oligospermia - epidemiology | Vincristine - administration & dosage | Adult | Female | Gonadotropin-Releasing Hormone - therapeutic use | Hodgkin Disease - physiopathology | Inhibins - blood | Menstrual Cycle - drug effects | Testosterone - blood | Menstrual Cycle - physiology | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Survivors | Etoposide - administration & dosage | Ovary - physiology | Hodgkin Disease - epidemiology | Bleomycin - administration & dosage | Bleomycin - adverse effects | Germany - epidemiology | Randomized Controlled Trials as Topic | Pregnancy | Testis - physiology | Hodgkin Disease - blood | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus
Journal Article
Bone marrow transplantation (Basingstoke), ISSN 1476-5365, 04/2010, Volume 46, Issue 1, pp. 98 - 104
Dyskeratosis congenita (DC) is characterized by reticular skin pigmentation, oral leukoplakia and abnormal nails. Patients with DC have very short telomeres... 
hematopoietic cell transplantation | dyskeratosis congenita | reduced-intensity conditioning regimen | Immunology | Life Sciences & Biomedicine | Hematology | Oncology | Transplantation | Biophysics | Science & Technology | Antibodies, Neoplasm - therapeutic use | Cyclophosphamide - administration & dosage | Peripheral Blood Stem Cell Transplantation - adverse effects | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Whole-Body Irradiation - adverse effects | Young Adult | Antibodies, Monoclonal, Humanized | Cord Blood Stem Cell Transplantation - adverse effects | Antineoplastic Agents - adverse effects | Dyskeratosis Congenita - therapy | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Pulmonary Fibrosis - etiology | Vidarabine - adverse effects | Vidarabine - analogs & derivatives | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | Vidarabine - therapeutic use | Combined Modality Therapy - adverse effects | Dyskeratosis Congenita - physiopathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Pulmonary Fibrosis - prevention & control | Bone Marrow Transplantation - adverse effects | Vidarabine - administration & dosage | Antibodies, Neoplasm - adverse effects | Epithelial cells | Patient outcomes | Abnormalities | Physiological aspects | Development and progression | Hematopoietic stem cells | Risk factors | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 646 - 653
Journal Article